Kimberly-Clark to buy Tylenol maker Kenvue in landmark $40bn merger
Kleenex maker’s deal for troubled Johnson & Johnson spinoff comes amid lawsuits and regulatory scrutinyKleenex maker Kimberly-Clark said on Monday it will buy Kenvue for more than $40bn in a landmark deal for the consumer sector, as the Tylenol maker grapples with White House scrutiny and...
<p>Kleenex maker’s deal for troubled Johnson & Johnson spinoff comes amid lawsuits and regulatory scrutiny</p><p>Kleenex maker Kimberly-Clark said on Monday it will buy Kenvue for more than $40bn in a landmark deal for the consumer sector, as the Tylenol maker grapples with White House scrutiny and choppy demand.</p><p>Kimberly-Clark would be scooping up the former <a href="https://www.theguardian.com/business/johnson---johnson">Johnson & Johnson</a> unit after months of struggles by Kenvue that include the ouster of its CEO in July and a share slump when <a href="https://www.theguardian.com/us-news/donaldtrump">Donald Trump</a> in September <a href="https://www.theguardian.com/us-news/2025/sep/22/trump-administration-autism-causes">asserted</a> that Tylenol use can lead to autism, a claim not backed by conclusive research.</p> <a href="https://www.theguardian.com/business/2025/nov/03/kimberly-clark-kleenex-tylenol-kenvue-merger">Continue reading...</a>
Read the full article at:
The Guardian World →